Join        Login             Stock Quote

Celgene (CELG) Initiated as 'Buy' By Brean Capital; PT $100

 November 21, 2012 01:38 PM

(By Balachander) Brean Capital LLC initiated shares of Celgene Corp. (NASDAQ: CELG) with a "buy" rating and price target of $100.

In the near term, CELG's share price is likely to be driven by how investors contemplate the peak revenue potential for Pomalidomide, Apremilast and Abraxane, in light of recent progress reported, the brokerage said.

"CELG has offered long-term guidance of achieving $8-9B in peak revenue by 2015, and our conservative estimates suggest the company will easily meet the low end of that guidance," Brean Capital said.

The brokerage expects regulatory submissions for Apremilast (psoriatic arthritis) and Abraxane (melanoma and pancreatic cancer) in early 2013, based on recent positive results from pivotal studies.

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

In addition, Brean Capital expects pivotal data for Apremilast in psoriasis indication from the ESTEEM Phase 3 program to be available starting YE12. Expansion into psoriasis could add up to $1B in additional peak revenue for Apremilast, the brokerage said.

The company currently markets Revlimid, and Thalomid for the treatment of various forms of multiple myeloma, and VIDAZA for the treatment of myelodysplastic syndromes.

Brean Capital expects Revlimid in multiple myeloma to remain CELG's largest, single revenue generator through patent expiration in 2027, yielding an additional $1B in revenue growth ($4.8B) by 2015 through expansion geographically and expansion in current and new myeloma settings.

[Related -Celgene Corporation (CELG): How Q3 Earnings Will Fare?]

CELG shares, which have been trading in the range of $58.53 to $81.24 over the past year, inched 0.88 percent higher to trade at $77.82 on Wednesday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Trying To Beat The Market Is A Fool's Errand
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.